close
References
  1. Kwatra SG. Breaking the itch-scratch cycle in prurigo nodularis. N Engl J Med. 2020;382(8):757-758.
  2. Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565.
  3. Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67-77.
  4. Aggarwal P, Choi J, Sutaria N, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277-1284.
  5. Todberg T, Zachariae C, Skov L. Treatment and burden of disease in a cohort of patients with prurigo nodularis: a survey-based study. Acta Derm Venereol. 2020;100(8):adv00119.
  6. Wongvibulsin S, Sutaria N, Williams KA, et al. A nationwide study of prurigo nodularis: disease burden and healthcare utilization in the United States. J Invest Dermatol. 2021;141(10):2530-2533.e1.
  7. Boozalis E, Tang O, Patel S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol. 2018;79(4):714-719.e3.
  8. Whang KA, Kang S, Kwatra SG. Inpatient burden of prurigo nodularis in the United States. Medicines (Basel). 2019;6(3):88.
  9. Whang KA, Khanna R, Thomas J, Aguh C, Kwatra SG. Racial and gender differences in the presentation of pruritus. Medicines (Basel). 2019;6(4):98.
  10. McColl M, Boozalis E, Aguh C, Eseonu AC, Okoye GA, Kwatra SG. Pruritus in black skin: unique molecular characteristics and clinical features. J Natl Med Assoc. 2021;113(1):30-38.
  11. Whang KA, Le TK, Khanna R, et al. Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol. 2021:S0190-9622(21)01028-8.
  12. Zeidler C, Tsianakas A, Pereira M, Ständer H, Yosipovitch G, Ständer S. Chronic prurigo of nodular type: a review. Acta Derm Venereol. 2018;98(2):173-179.
  13. Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747-760.
  14. Haydek CG, Love E, Mollanazar NK, et al. Validation and banding of the ItchyQuant: a self-report itch severity scale. J Invest Dermatol. 2017;137(1):57-61.
  15. Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.e4.
  16. Böhme T, Heitkemper T, Mettang T, Phan NQ, Ständer S. Klinische charakteristika und prurigo nodularis bei nephrogenem pruritus [Clinical features and prurigo nodularis in nephrogenic pruritus]. Hautarzt. 2014;65(8):714-720.
  17. Swarna SS, Aziz K, Zubair T, Qadir N, Khan M. Pruritus associated with chronic kidney disease: a comprehensive literature review. Cureus. 2019;11(7):e5256.
  18. Weber B, Merola JF, Husni ME, Di Carli M, Berger JS, Garshick MS. Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics. Curr Atheroscler Rep. 2021;23(11):67.
  19. Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):2211.
  20. Forouzandeh M, Stratman S, Yosipovitch G. The treatment of Kyrle's disease: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1457-1463.
  21. Larson VA, Tang O, Stander S, Miller LS, Kang S, Kwatra SG. Association between prurigo nodularis and malignancy in middle-aged adults. J Am Acad Dermatol. 2019;81(5):1198-1201.
  22. Johannesdottir SA, Farkas DK, Vinding GR, et al. Cancer incidence among patients with a hospital diagnosis of pruritus: a nationwide Danish cohort study. Br J Dermatol. 2014;171(4):839-846.
  23. Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567-1575.
  24. Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021;9(3):303.
  25. Müller S, Bieber T, Ständer S. Therapeutic potential of biologics in prurigo nodularis. Expert Opin Biol Ther. 2021. [Epub ahead of print].
  26. Schmelz M. Itch and pain differences and commonalities. Handb Exp Pharmacol. 2015;227:285-301.
  27. Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol. 2011;165(1):85-91.
  28. Gründel S, Pereira MP, Storck M, et al. Analysis of 325 patients with chronic nodular prurigo: clinics, burden of disease and course of treatment. Acta Derm Venereol. 2020;100(16):adv00269.
  29. Clinicaltrials.gov. Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (PRIME). clinicaltrials.gov/ct2/show/NCT04183335. Accessed September 29, 2021.
  30. Clinicaltrials.gov. Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (PRIME2). clinicaltrials.gov/ct2/show/NCT04202679. Accessed September 29, 2021.
  31. Clinicaltrials.gov. A study to assess the efficacy and safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN). clinicaltrials.gov/ct2/show/NCT04501679. Accessed September 29, 2021.
  32. Clinicaltrials.gov. An efficacy and safety study of nemolizumab (CD14152) in participants with prurigo nodularis. clinicaltrials.gov/ct2/show/NCT04501666. Accessed September 29, 2021.
  33. Clinicaltrials.gov. A long-term study of nemolizumab (CD14152) in participants with prurigo nodularis (PN). clinicaltrials.gov/ct2/show/NCT04204616. Accessed September 29, 2021.
  34. Clinicaltrials.gov. A study to evaluate the durability of response and safety of nemolizumab for 24 weeks in participants with prurigo nodularis. clinicaltrials.gov/ct2/show/NCT05052983. Accessed September 29, 2021.
  35. Clinicaltrials.gov. Study to assess the efficacy, safety, and tolerability of vixarelimab in reducing pruritus in prurigo nodularis. clinicaltrials.gov/ct2/show/NCT03816891. Accessed September 29, 2021.
  36. Clinicaltrials.gov. PRISM study-pruritus relief through itch scratch modulation (PRISM). clinicaltrials.gov/ct2/show/NCT03497975. Accessed September 29, 2021
  37. Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: a review of present indications and uses out of indication. J Investig Allergol Clin Immunol. 2021. [Epub ahead of print].
  38. Husein-ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat. 2021. [Epub ahead of print].
  39. Olesen CM, Holm JG, Nørreslet LB, Serup JV, Thomsen SF, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol. 2019;33(8):1562-1568.
  40. Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol. 2019;181(5):1072-1074.
  41. Calugareanu A, Jachiet M, Tauber M, et al; French Group of Research and Study in Atopic Dermatitis (Groupe de Recherche sur l'Eczéma Atopique, GREAT) from the French Society of Dermatology (SFD). Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur Acad Dermatol Venereol. 2020;34(2):e74-e76.
  42. Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39-45.
  43. DUPIXENT (dupilumab) [package insert]. Regeneron Pharmaceuticals, Inc.; 2021.
  44. Yosipovitch G, Mollanazar N, Ständer S, et al. The study design of two trials of dupilumab in patients with prurigo nodularis inadequately controlled with topical therapies: LIBERTY PN PRIME and PRIME 2. J Invest Dermatol. 2021;141(suppl 5):S75.
  45. Regeneron press release. Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease. October 22, 2021.
  46. Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382(8):706-716.
  47. Galderma press release. Galderma presents new nemolizumab data at EADV reinforcing rapid onset of action and consistent relief of symptoms for people with prurigo nodularis and atopic dermatitis. September 29, 2021.
  48. Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med (Lausanne). 2021;8:638325.
  49. Inan S, Cowan A. Antipruritic effects of kappa opioid receptor agonists: evidence from rodents to humans. Handb Exp Pharmacol. 2021. [Epub ahead of print].
  50. Hawi A, Alcorn H Jr, Berg J, Hines C, Hait H, Sciascia T. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol. 2015;16:47.
  51. Jannuzzi RG. Nalbuphine for treatment of opioid-induced pruritus: a systematic review of literature. Clin J Pain. 2016;32(1):87-93.
  52. American Journal of Managed Care. Profiles in care: importance of a coordinated health care plan in plaque psoriasis and psoriatic arthritis management. www.ajmc.com/view/profiles-in-care-importance-of-a-coordinated-health-care-plan-in-plaque-psoriasis-and-psoriatic-arthritis-management. Published July 20, 2021. Accessed October 11, 2021.
  53. Kwon CD, Khanna R, Williams KA, Kwatra MM, Kwatra SG. Diagnostic workup and evaluation of patients with prurigo nodularis. Medicines (Basel). 2019;6(4):97.